Stock Isn’t Cheap but Still Worth Buying? Three Hard Reasons Behind Eli Lilly Explained May 4, 2026 Life Science
Dark Horse in the Weight-Loss Drug Arena? Viking Therapeutics Has Potential Upside of Over 200% May 4, 2026 Life Science
Want to Build Real Wealth in the Healthcare Sector? These Stocks Are Worth Considering Apr 30, 2026 Life Science
Shorted-to-The-Hilt KalVista Rockets 39% as Chiesi Swoops in With $1.9bn Cash Bid Apr 29, 2026 Life Science
From Weight Loss to Cancer Treatment Drugs, Eli Lilly Has More Than One Ace in the Hole Apr 28, 2026 Life Science
Organon Shares Extend Rally as India’s Sun Pharma Strikes $11.75 Billion All-Cash Deal Apr 27, 2026 Life Science
Teva Pharmaceuticals to Release Quarterly Report, Analysts Suggest Waiting for Post-Earnings Purchase Apr 27, 2026 Life Science
Can the New Weight-Loss Drug Foundayo from Eli Lilly Replicate Its Blockbuster Success? Early Data Raises Market Concerns Apr 25, 2026 Life Science
Aaron Wealth Advisors Increases Stake in MBX Biosciences, Betting on Precision Peptide Therapies for Rare Diseases Apr 23, 2026 Life Science
CVS Health’s Transformation Is Underestimated by the Market, with Three Major Reasons Highlighting Its Value Stock Potential Apr 23, 2026 Life Science
UnitedHealth’s Q1 Performance Exceeds Expectations, Early Returns Seen from AI Investments Apr 21, 2026 Life Science
Positive Clinical Data for Hair Loss Treatment Drives Nektar Therapeutics Stock to Surge in a Single Day Apr 21, 2026 Life Science
Trump Orders Fast-Track for Psychedelic Therapies—Who Stands to Win the Most? Apr 20, 2026 Life Science
Lilly in Advanced Talks to Acquire Kelonia for Over $2 Billion—Is a 39x P/E Still Too Rich? Apr 19, 2026 Life Science
No Longer Afraid of Injections, Eli Lilly’s Oral Weight Loss Drug Foundayo Targets a Multibillion-Dollar Market Apr 17, 2026 Life Science
